220 related articles for article (PubMed ID: 24928343)
1. Disease-modifying anti-rheumatic drugs improve autonomic neuropathy in arthritis: DIANA study.
Syngle A; Verma I; Krishan P; Garg N; Syngle V
Clin Rheumatol; 2015 Jul; 34(7):1233-41. PubMed ID: 24928343
[TBL] [Abstract][Full Text] [Related]
2. Predictors of autonomic neuropathy in rheumatoid arthritis.
Syngle V; Syngle A; Garg N; Krishan P; Verma I
Auton Neurosci; 2016 Dec; 201():54-59. PubMed ID: 27503343
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis.
Syngle A; Verma I; Krishan P; Syngle V
Ther Adv Musculoskelet Dis; 2016 Apr; 8(2):42-8. PubMed ID: 27047572
[TBL] [Abstract][Full Text] [Related]
4. Autonomic dysfunction in psoriatic arthritis.
Syngle A; Verma I; Garg N; Krishan P
Clin Rheumatol; 2013 Jul; 32(7):1059-64. PubMed ID: 23549640
[TBL] [Abstract][Full Text] [Related]
5. Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk.
Milovanović B; Stojanović L; Milićevik N; Vasić K; Bjelaković B; Krotin M
Srp Arh Celok Lek; 2010; 138(1-2):26-32. PubMed ID: 20422909
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular autonomic neuropathy in rheumatoid arthritis assessed by cardiovascular autonomic function tests: A cross-sectional survey.
Javady Nejad Z; Jamshidi AR; Qorbani M; Ravanasa P
Anatol J Cardiol; 2015 Sep; 15(9):722-6. PubMed ID: 25592093
[TBL] [Abstract][Full Text] [Related]
7. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases.
Stojanovich L; Milovanovich B; de Luka SR; Popovich-Kuzmanovich D; Bisenich V; Djukanovich B; Randjelovich T; Krotin M
Lupus; 2007; 16(3):181-5. PubMed ID: 17432103
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis.
Haibel H; Specker C
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S159-63. PubMed ID: 19822065
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 blockade improves autonomic dysfunction in rheumatoid arthritis.
Syngle A; Verma I; Krishan P
Acta Reumatol Port; 2015; 40(1):85-8. PubMed ID: 24863079
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
13. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
14. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.
Steiman AJ; Pope JE; Thiessen-Philbrook H; Li L; Barnabe C; Kalache F; Kung T; Bessette L; Flanagan C; Haraoui B; Hochman J; Leclercq S; Mosher D; Thorne C; Bykerk V
Rheumatol Int; 2013 May; 33(5):1105-20. PubMed ID: 23292213
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.
Syngle A; Chahal S; Vohra K
Neurol Sci; 2021 Apr; 42(4):1429-1436. PubMed ID: 32803534
[TBL] [Abstract][Full Text] [Related]
16. Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.
Roussy JP; Bessette L; Bernatsky S; Rahme E; Lachaine J
Osteoporos Int; 2013 Sep; 24(9):2483-92. PubMed ID: 23504029
[TBL] [Abstract][Full Text] [Related]
17. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
[TBL] [Abstract][Full Text] [Related]
18. Treatment of rheumatoid arthritis and ankylosing spondylitis.
Braun J; Sieper J
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S146-7. PubMed ID: 19822062
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular parasympathetic nervous system dysfunction in female rheumatoid arthritis patients.
Saraswathi PV; Neelambikai N; Mahesh A; Govindarajan K
Indian J Physiol Pharmacol; 2013; 57(1):23-30. PubMed ID: 24020095
[TBL] [Abstract][Full Text] [Related]
20. Prescription rheumatology practices among Mexican specialists.
Goycochea-Robles MV; Arce-Salinas CA; Guzmán-Vázquez S; Cardiel-Ríos MH
Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
